Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject or subject´s legally authorized representative has provided written informed consent~* Subject is 18 years of age or older~* Subject has a documented, endogenous plasma Alpha1-PI level \< 8 Micromolar~* Subject is of the genotype Pi\*Z/Z, Pi\*Z/Null, Pi\*Null/Null, Pi\*Malton/Z, or others, dependent on the approval by the Sponsor~* If the subject is female or of childbearing potential, the subject has a negative urine test for pregnancy within 7 days prior to first study product administration and agrees to employ adequate birth control measures for the duration of the study~* Laboratory results obtained at the screening visit, meeting the following criteria:~  * Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) \<= 2 times the upper limit of normal (ULN)~ * Serum total bilirubin \<= 2 times ULN~ * Proteinuria \< +2 on dipstick analysis~ * Serum creatinine \<= 1.5 times ULN~ * Absolute neutrophil count (ANC) \>= 1500 cells/mm3~ * Hemoglobin \>= 10.0 g/dL~ * Platelet count \>= 10\^5/mm3~* If the subject is treated with any respiratory medications, including inhaled bronchodilators and inhaled or oral corticosteroids, the subjects´ medication doses were unchanged for at least 14 days prior to first study product administration~* Nonsmoker for a minimum of 3 months prior to first study product administration~Exclusion Criteria:~* The subject has received any Alpha1-PI augmentation therapy (including Aralast and investigational Alpha1-PIs, by any route including intravenous and inhaled) within 42 days prior to first study product administration~* The subject has received an investigational drug or device within 1 month prior to first study product administration, or the subject is currently receiving an investigational drug~* The subject has a known selective immunoglobulin A (IgA) deficiency (IgA level \< 15 mg/dL) and/or antibody to IgA~* The subject has a pulmonary exacerbation or had a pulmonary exacerbation in the past 14 days prior to first study product administration~* The subject is pregnant or lactating, or intends to become pregnant during the course of the study~* The subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARALAST Fr. IV-1 (Type: EXPERIMENTAL): 60 mg/kg
- ARALAST (Type: ACTIVE_COMPARATOR): 60mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).